Results 31 to 40 of about 30,781 (201)

Association of KDR rs1870377 genotype with clopidogrel resistance in patients with post percutaneous coronary intervention [PDF]

Heliyon, 2021
Hamzeh J Al-Ameer, Yazun Jarrar, Ghizal Fatima   +2 more
exaly   +2 more sources

Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease. [PDF]

PLoS ONE, 2014
Clopidogrel is an antiplatelet prodrug that is recommended to reduce the risk of recurrent thrombosis in coronary artery disease (CAD) patients. Paraoxonase 1 (PON1) is suggested to be a rate-limiting enzyme in the conversion of 2-oxo-clopidogrel to ...
Damrus Tresukosol, Bhoom Suktitipat, Saowalak Hunnangkul, Ruttakarn Kamkaew, Saiphon Poldee, Boonrat Tassaneetrithep, Atip Likidlilid   +6 more
doaj   +1 more source

Analysis of CYP2C19 gene polymorphism and influencing factors of pharmacological response of clopidogrel in patients with cerebral infarction in Zhejiang, China

Frontiers in Cardiovascular Medicine, 2023
BackgroundCertain genetic and non-genetic factors may cause damaged platelet inhibition by clopidogrel. We aimed to determine the effect of cytochrome P4502C19 (CYP2C19) polymorphism, along with other clinical factors, on the platelet response to ...
Yijun Mo, Yao Lu, Fei Guo, Aihua Wu, Yuesong Weng   +4 more
doaj   +1 more source

Clinical importance of testing for clopidogrel resistance in patients undergoing carotid artery stenting-a systematic review. [PDF]

Ann Transl Med, 2021
Dual antiplatelet therapy is frequently prescribed for patients undergoing carotid artery stenting (CAS), however clopidogrel resistance might cause thromboembolic complications.
Collette SL, Bokkers RPH, Dierckx RAJO, van der Laan MJ, Zeebregts CJ, Uyttenboogaart M.   +5 more
europepmc   +2 more sources

Assessment of Risk Factors for Drug Resistance of Dual Anti Platelet Therapy After PCI

Clinical and Applied Thrombosis/Hemostasis, 2022
Since aspirin and clopidogrel are the widely and conventionally used drugs to treat acute myocardial infarction after percutaneous coronary intervention (PCI), it is important to explore potential risk factors of their resistance.
Lijie Zhang PhD, MD, Ying Lv PhD, MD, Jianyu Dong PhD, MD, Nana Wang MSc, Zhan Zhan MSc, Yuan Zhao BSc, Shanshan Jiang PhD, MD   +6 more
doaj   +1 more source

Increase in the risk of clopidogrel resistance and consequent TIMI flow impairment by DNA hypomethylation of CYP2C19 gene in STEMI patients undergoing primary percutaneous coronary intervention (PPCI)

Pharmacology Research & Perspectives, 2021
Clopidogrel resistance is an important risk factor of ischemic event recurrence after optimal antiplatelet therapy. This study aims to investigate the role of CYP2C19 gene DNA methylation as one of the epigenetic factors for the risk of clopidogrel ...
Renan Sukmawan, Erick Hoetama, Siska Suridanda Danny, Astuti Giantini, Erlin Listiyaningsih, Vidya Gilang Rejeki, Amir Aziz Alkatiri, Isman Firdaus   +7 more
doaj   +1 more source

Periodontitis and atherosclerotic cardiovascular disease: A critical appraisal

Periodontology 2000, EarlyView., 2023
Abstract In spite of intensive research efforts driving spectacular advances in terms of prevention and treatments, cardiovascular diseases (CVDs) remain a leading health burden, accounting for 32% of all deaths (World Health Organization. “Cardiovascular Diseases (CVDs).” WHO, February 1, 2017, https://www.who.int/news‐room/fact‐sheets/detail ...
Maria Clotilde Carra, Hélène Rangé, Giuseppina Caligiuri, Philippe Bouchard   +3 more
wiley   +1 more source

Influence of genetic polymorphisms in P2Y12 receptor signaling pathway on antiplatelet response to clopidogrel in coronary heart disease

BMC Cardiovascular Disorders, 2022
Backgrounds Remarkable interindividual variability in clopidogrel response is observed, genetic polymorphisms in P2RY12 and its signal pathway is supposed to affect clopidogrel response in CHD patients.
Yan-Jiao Zhang, Dong-Jie Li, Zhong-Yi Li, Xiao-Lei Hu, He Li, Qi-Lin Ma, Xiao-Ping Chen   +6 more
doaj   +1 more source

Drug interactions and hepatotoxicity of clopidogrel [PDF]

, 2010
Clopidogrel (Plavix¨) is an antiplatelet drug, which is clinically used in combination with aspirin to reduce cardiovascular events in patients undergoing percutaneous coronary intervention or in patients suffering from acute coronary syndromes ...
Zahno, Anja-Christina
core   +1 more source

The stent thrombosis in Belgium (STIB) scoring system reliability in Indonesia patients and the modified STIB scoring (M-STIB)

The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2023
Introduction Clopidogrel is recommended as an alternative to Acetyl Salicylic Acid (ASA), the first-line drug for secondary stroke prevention. Clopidogrel resistance in Indonesia is reportedly 15.8%.
Rakhmad Hidayat, Al Rasyid, Salim Harris, Alida R. Harahap, Herqutanto, Melva Louisa, Erlin Listiyaningsih, Aldy Safruddin Rambe, Tonny Loho   +8 more
doaj   +1 more source